Voriconazole-induced QT-corrected (QTc) interval prolongation, bradycardia, hypothermia, mydriasis in an immunosuppressed patient with Ewing.

Sub-category: Supportive Care
Category: Patient and Survivor Care
Meeting: 2009 ASCO Annual Meeting
Session Type and Session Title: This abstract will not be presented at the 2009 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract No: e20738
Citation: J Clin Oncol 27, 2009 (suppl; abstr e20738)
Author(s): S. Alkhallaf, H. Cornille, B. Markowska, Z. Lankri, N. Delepine; Raymond Poincare Hospital, Garches, France
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract:

Background: Invasive aspergillosis is an important cause of increased mortality and morbidity in immunocompromised patients. Early treatment of probable aspergillosis by voriconazole is recommended by many authors. Nevertheless direct possible lethal complications must be taken into account. Methods: we describe a case of voriconazole adverse events in a 18 y old patient treated for aplasia by antibiotics and caspofungin. He remained febrile: Voriconazole initiated for digestive mycosis, caugh, endemic aspergillosis. Second injection was badly tolerated ( fever 40 °, dyspnea, chills, myalgias, hypotension) leading to stop Voriconazole. Few hours later, bradycardia (36 bpm/mn), QT c interval prolongation (QTc 482ms), bilateral mydriasis, hypothermia appeared. Others risks for cardiac events were studied: prior cardiotoxic chemotherapy; lightly low calcemia and magenesemia , negative T ondes, traducing major potassium deficit in cardiac cells, in spite of initially normal kaliemia (4.6 mmol/l) mild hypokalemia (3.3 meq/l). Systemic infection was eliminated, cerebral MRI normal, blood dosage of voriconazole at 80 h and 96 h after last dose negative. We discontinued potentially arrhythmogenic drugs. Specific treatment consisted of electrolyte disturbances correction, IV atroine, scopilamine patch. 24 h holter ECG revealed neither torsades de pointes nor ventricular tachycardia. QT c interval remained longer for 3 days. Onde T was normalised at day 6, with disappearance of bradycardia and hypothermia ,without any cardiac event. Results: Azole family antifungal agents were pointed out as arrhythmogenic (QTc prolongation, torsades de pointes) in combination or alone. Few data reported bradycardia and QT c prolongation with voriconazole, although the drug package insert warns about such reactions. Furthermore, none case of mydriasis was reported but noted in Pfizer American data file(< 2% of case). Conclusions: Careful monitoring of QTc prolongation and bradycardia in patients receiving voriconazole is mandatory, particularly those with electrolyte disturbances, concomitant QT prolonging drugs, and /or receiving toxic cardiac chemotherapy.

Associated Presentation(s):
No items found.

Other Abstracts in this Sub-Category:

1. A survey of U.S. and Canadian oncologists' attitudes toward the cost, cost-effectiveness (CE), and reimbursement of cancer drugs.
   
   Meeting: 2009 ASCO Annual Meeting   Abstract No: 9502   First Author: P. Neumann
   Category: Patient and Survivor Care - Supportive Care

2. Pregabalin for hot flashes in women: NCCTG trial N07C1.
   
   Meeting: 2009 ASCO Annual Meeting   Abstract No: 9513   First Author: C. L. Loprinzi
   Category: Patient and Survivor Care - Supportive Care

   
   Category: Patient and Survivor Care - Supportive Care

More...

Abstracts by S. Alkhallaf:

   
   Meeting: 2011 ASCO Annual Meeting   Abstract No: e20005   First Author: H. Cornille
   Category: Pediatric Oncology - Pediatric Solid Tumors

2. Voriconazole-induced QT-corrected (QTc) interval prolongation, bradycardia, hypothermia, mydriasis in an immunosuppressed patient with Ewing.
   
   Meeting: 2009 ASCO Annual Meeting   Abstract No: e20738   First Author: S. Alkhallaf
   Category: Patient and Survivor Care - Supportive Care

More...

Presentations by S. Alkhallaf:

No items found.

Educational Book Manuscripts by S. Alkhallaf:

No items found.